ProMetic Receives $5.1M Order from Multinational Client

ProMetic Life Sciences

announced today that it has received a $5.1 million purchase order for the supply of affinity resin from an existing client, a global leader in the biotherapeutics industry. This order represents the first purchase order issued resulting from the licence and long-term supply agreement previously announced on July 8th 2013. The affinity resin will be manufactured by ProMetic at its Isle of Man production facility and supplied to the client throughout 2014 and early 2015. ProMetic's client will use the resin for large-scale purification of a therapeutic protein product and it is anticipated further orders will be received once the current order is completed."This order for affinity resin provides confirmation of the rapidly growing demand for this particular product and is completely in-alignment with ProMetic's expectations" said Dr. Steve Burton, Chief Executive Officer of ProMetic BioSciences Ltd. "We are now seeing real and significant growth in demand for our affinity purification products as our clients recognise the value that ProMetic's technology provides with respect to market advantage and reduction of process costs", added Dr. Burton. Mr Pierre Laurin, President and CEO of ProMetic said